Over the past few months, thousands of people in India who survived Covid-19 returned to hospitals with a rare and life-threatening infection called mucormycosis, or black fungus. But the medicine used to treat the infection is in short supply and priced out of reach for many people, according to dozens of advocacy groups that are urging the manufacturer to quickly widen access.
At issue is amphotericin B, which is marketed by Gilead Sciences (GILD) to combat cryptococcal meningitis in patients with HIV or visceral leishmaniasis, a parasitic disease. But the sudden emergence of black fungus has opened the company to criticism that it failed to ensure a predictable and affordable supply of the intravenous drug. The infection, which has an overall mortality rate of 50%, may be being triggered by the use of steroids, a life-saving treatment for severe and critically ill Covid-19 patients.
This blog is for information purposes only. The content is not intended as medical advice, diagnosis, or treatment. Should you have a medical or dermatological problem, please consult with your physician. None of the information or recommendations on this website should be interpreted as medical advice.
All product reviews, recommendations, and references are based on the author’s personal experience and impressions using the products. All views and opinions are the author’s own.
This blog post may contain affiliate links. An affiliate link means we may earn a commission if you click on a link and make a purchase, without any extra cost to you.
Please see our Disclaimer for more information.